Source: Annual Congress 2005 - Lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
F. Le Calvez, A. Mukeria, J. D. Hunt, O. Kelm, R. J. Hung, P. Taniere, P. Brennan, P. Boffetta, D. G. Zaridze, P. Hainaut, E. Brambilla (Lyon, Grenoble, France; Moscow, Russian Federation; New Orleans, USA; Birmingham, UK). Mutation of TP53 and KRAS, and loss of p16^ink4a and p14^arf expression in lung cancers in relation to tobacco smoke. Eur Respir J 2005; 26: Suppl. 49, 675

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Source: Eur Respir J 2014; 43: 872-883 Year: 2014 KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017 Evaluation of EGFR mutations and ERCC2 polymorphisms in treatment of non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases Source: Eur Respir J 2016; 48: 1462-1470 Year: 2016 The analysis of CHEK2 gene mutation in small cell lung cancer Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Mutant P53 expression in squamous cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 LSC - 2017 - KRAS & TP53 mutations cause malignant mesothelioma Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside Year: 2017 MDM2 gene amplification and mdm2 protein expression in NSCLC cells Source: Eur Respir J 2005; 26: Suppl. 49, 91s Year: 2005 Studies on clinical significance and relationship with PI and gene protein expression of p16, Rb and Cyclin-D1 in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002